Alzheimer’s disease and stem cell therapy part 21

Stem cell 5

 

There have been recent encouraging results in animal studies with administration of beta-amyloid antibodies to mice in order decrease beta-amyloid. They showed the recovery of acetylcholine release and choline absorption in the hippocampus. The learning capacity was also improved. The results have led to related clinical trials in humans. Continuous reduction of beta-amyloid might be another method of addressing  alzheimers. This can be done with proteases such as neprilysin, insulin-degrading enzyme, plasmin, and cathepsin B. The intraventricular injection of the human neprilysin gene expressing viruses  into amyloid transgenic mouse models has contributed to a decrease in beta-amyloid  aggregation and  neuronal degradation in the frontal cortex and hippocampus. According to a report, intraventricular injections of the human neprilysine gene expressing fibroblasts into beta-amyloid aggregation transgenic mouse models have resulted  in a considerable decrease of amyloid plaques. These studies have provided the evidence that proteases can be used as beta-amyloid reducing therapeutic agents on account of their function of decomposing beta-amyloid and paved the way for cure-oriented studies that focus on protease-expressing neural stem cells.

Advertisements

About azaleaazelia

A nice person... :)
This entry was posted in Tak Berkategori. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s